MedTrace Logo

Cognition in the Study of Tamoxifen and Raloxifene

NCT00687102 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1498

Last updated 2018-09-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effects of tamoxifen and raloxifene on cognitive aging in selected cognitively-healthy women.

Conditions

  • Cognition
  • Aging

Interventions

DRUG

tamoxifen

oral tamoxifen plus placebo daily for 5 years

DRUG

raloxifene

oral raloxifene plus placebo daily for 5 years

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Wake Forest University

    lead OTHER

Principal Investigators

  • Sally A. Shumaker, PhD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2008-03-31
Completion
2008-03-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00687102 on ClinicalTrials.gov